PBRT20077 / ACNS1831 / Korones
Basic Study Information
Purpose:
This phase III trial studies if selumetinib works just as well as the standard treatment
with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma
(LGG), and to see if selumetinib is better than CV in improving vision in subjects
with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by
blocking some enzymes that low-grade glioma tumor cells need for their growth. This
results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and
vincristine, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether selumetinib works better in treating patients with NF1-associated
low-grade glioma compared to standard therapy with carboplatin and vincristine.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
David Korones
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search